About Us

About Us

About Us Aligos is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of our...
Company Mission

Company Mission

Curative Therapies Duis ligula libero lacinia Company Mission To become a world leader in the development of targeted, curative therapies for hepatologic diseases and viral infections including chronic hepatitis B (CHB), non-alcoholic steatohepatitis...
Contact

Contact

Aligos’ Locations US Office 1 Corporate Dr., 2nd Floor South San Francisco, CA 94080 info@aligos.com Gaston Geenslaan 1 / (building 3) 3001 Leuven, Belgium info@aligos.com European Office ...

Home

Our Missiona To become a world leader in developing targeted therapies for hepatologic diseases and viral infections, including CHB, nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) and COVID-19, which collectively affect hundreds...

Home

Our Mission To become a world leader in developing targeted therapies for hepatologic diseases and viral infections, including CHB, nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) and COVID-19, which collectively affect hundreds...
Investors

Investors

Working out of Copenhagen, with affiliates in San Francisco and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value. The Roche Venture Fund invests in early stage biotech, digital...
Management Team

Management Team

Management Team Board of Directors Management Team Lawrence Blatt, Ph.D., MBA Chief Executive Officer Global Infectious Diseases Therapeutic Area Head – Janssen Co-Founder, Chief Executive Officer – Alios BioPharma C...
Partners

Partners

In June 2018, Aligos entered into an agreement with Emory University whereby Aligos acquired from Emory an exclusive license to technology with respect to a novel class of non-nucleoside class-II capsid assembly modulators. The underlying technology...
Platform & Pipeline

Platform & Pipeline

With Aligos’ extensive expertise and experience in developing therapeutics for chronic liver diseases, we are building a robust pipeline of best-in-class drug candidates focused on developing curative therapies for chronic Hepatitis B and delivering transformative treatments in other areas of liver disease. Development Pipeline Aligos Therapeutics is targeting multiple, clinically validated mechanisms of action to develop functionally curative therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Chronic hepatitis B Chronic hepatitis B (CHB) is the chronic presentation of hepatitis B virus (HBV) infection, which causes damaging liver inflammation in the long term. CHB is the most common chronic viral infection globally and is a potentially life-threatening disease. However, CHB has no functional cure, or durable disappearance of signs of disease following a finite course of treatment. Despite an available vaccine, its incidence remains high in some regions, and at-risk patient populations face dramatically elevated risks of cirrhosis and hepatocellular carcinoma (HCC), as currently available treatments fail to effectively clear the virus. With the aim of introducing high rates of functional cure in CHB for the first time, Aligos’ strategy is to develop a combination of highly effective therapeutics, each targeting distinct mechanisms of action, with additive to synergistic effects when used together. This strategy has been highly effective in the treatment of other chronic viral diseases such as chronic hepatitis C and human immunodeficiency virus (HIV). Aligos is developing three candidates called STOPS™, ASOs, and CAMs that target clinically validated mechanisms for inhibition of the HBV life cycle. These candidates are designed to reduce an HBV antigen called HBsAg or S-antigen while fully suppressing HBV replication, a new approach that may lead to functional cure in a large percentage of CHB patents. Aligos wholly owns the technology underlying each of the candidates and can advance rapidly to triple-combination trials to evaluate these candidates’ potential for achieving functional cure. Chronic hepatitis B candidates: components of a combination approach CAMs (Capsid Assembly Modulators) : Suppressing HBV replication: CAMs are small molecules that interfere with HBV capsid formation and viral replication. In clinical trials, CAMs have demonstrated significant reductions in HBV DNA and RNA 1,2 . Aligos is optimizing proprietary CAM candidates that have demonstrated higher potency in preclinical studies compared to CAM molecules currently in clinical development. Aligos’ lead molecule ALG-000184, has best-in-class properties will enter the clinic in the second half of 2020. Also known as HBV core inhibitors, CAMs are allosteric inhibitors that interfere with the formation of intact and thus infectious virus particles, thereby inhibiting HBV genome replication, covalently closed circular DNA (cccDNA) formation and cccDNA maintenance. In the presence of Class I CAMs, aberrantly shaped viral particles are produced. In the presence of Class II CAMs, non-infectious empty viral particles are produced.. Aligos has identified multiple promising Class II and Class I CAMs that are currently being optimized. STOPS™* (S-antigen Transport-inhibiting Oligonucleotide Polymers): Suppressing S-antigen: Surface antigen, or S-antigen, expressed by HBV is believed to suppress the host’s immune system in the setting of CHB and likely prevents viral clearance in a large proportion of CHB cases4 . Current CHB therapies do not meaningfully affect S-antigen levels in most patients, a key shortcoming in attempting to achieve functional cure 5 . Aligos has developed STOPS, based on novel oligonucleotide technology closely related to nucleic acid polymers (NAPs), which have demonstrated unprecedented S-antigen reduction in preclinical studies and in CHB clinical trials3 . STOPS were designed to mediate the degradation of S-antigen, thereby eliminating one of the most important mechanisms for chronic CHB infection. Aligos’ lead STOPS candidate, ALG-010133, is positioned to enter the clinic in the second half of 2020. ASOs (Antisense oligonucleotides)*: Suppressing S-antigen:   ASOs are a selective means of targeting the genetic basis of disease. In the case of HBV, Aligos is developing ASOs to inhibit viral messenger RNA (mRNA) transcripts that encode the S-antigen to reduce S-antigen levels in CHB. The company has selected a best-in-class pair of ASOs as a two-trigger system to target S-antigen, potentially in a synergistic fashion with STOPS therapies.ASOs bind to complementary messenger RNAs (mRNAs) and trigger their degradation via the enzyme ribonuclease H (RNAse H). ASOs can therefore be used to target viral mRNAs such as those encoding the S-antigen to lower S-antigenlevels and enable reconstitution of the host immune system against the virus. Aligos has a number of ASOs in development that may offer best-in-class properties compared to other oligonucleotide approaches currently in the clinic. THR-β (Thyroid hormone receptor beta) agonists: Thyroid hormone receptors (THRs) are composed of two main sub-classes (alpha and beta) that are stimulated by the thyroid hormone, triiodothyronine (T3). Over stimulation of THR alpha results in tachycardia, bone loss, and muscle wasting, while THR beta stimulation primarily affects the liver and results in reductions in lipids, including cholesterol, triglycerides, and liver fats (steatosis). Therefore, selective stimulation of THR-β receptors has the potential to reduce a patient’s lipid burden, including the steatosis which underpins NASH, while avoiding unwanted THR alpha-mediated side effects. Indeed, several THR-β agonists are in the clinic and have demonstrated favorable effects on plasma lipid levels, liver fat burden, as well as liver histology 6,7 in NASH patients. Aligos has THR-β agonists in development that may offer best-in-class properties compared to other compounds currently in the clinic. Aligos is currently optimizing and validating a number of compounds targeting undisclosed mechanisms of action are thought to be central to the pathogenesis of HCC.
Presentation

Presentation

Presentation Jefferies Healthcare Conference, June 4, 2020 View Presentation
Press & Publications

Press & Publications

Sed in bibendum velit. Suspendisse ullamcorper sapien orci San Joe, June 21, 2018 – Donec gravida dui et sagittis elementum. Sed in bibendum velit. Suspendisse ullamcorper sapien orci, tempus luctus magna lobortis sed. Sed orci erat, euismod vel d...

Privacy Policy

Privacy Policy Who we are Our website address is: http://localhost/aligos. What personal data we collect and why we collect it Comments When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s I...